CEO: Richard M. Glickman

Sector: Healthcare
Industry:Biotechnology

Exchange: NASDAQ Global Market

Country: USA

Description: Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.


Key numbers

Market Capitalization:1751309120
Shares Outstanding: 112552000
Float: 88547135
Next Earning Date:
TTm EPS: -1.308
TTm Dividend Rate:
200 days moving average:13.88
50 days moving average: 16.21
One day percent Change: -2.45



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,